The evolution and clinical impact of hepatitis B virus genome diversity

Peter A. Revill,Thomas Tu,Hans J. Netter,Lilly K. W. Yuen,Stephen A. Locarnini,Margaret Littlejohn
DOI: https://doi.org/10.1038/s41575-020-0296-6
2020-05-28
Abstract:The global burden of hepatitis B virus (HBV) is enormous, with 257 million persons chronically infected, resulting in more than 880,000 deaths per year worldwide. HBV exists as nine different genotypes, which differ in disease progression, natural history and response to therapy. HBV is an ancient virus, with the latest reports greatly expanding the host range of the Hepadnaviridae (to include fish and reptiles) and casting new light on the origins and evolution of this viral family. Although there is an effective preventive vaccine, there is no cure for chronic hepatitis B, largely owing to the persistence of a viral minichromosome that is not targeted by current therapies. HBV persistence is also facilitated through aberrant host immune responses, possibly due to the diverse intra-host viral populations that can respond to host-mounted and therapeutic selection pressures. This Review summarizes current knowledge on the influence of HBV diversity on disease progression and treatment response and the potential effect on new HBV therapies in the pipeline. The mechanisms by which HBV diversity can occur both within the individual host and at a population level are also discussed.
gastroenterology & hepatology
What problem does this paper attempt to address?
The problems that this paper attempts to solve are the global burden of chronic hepatitis B (CHB) and its treatment challenges. Specifically: 1. **The impact of viral diversity on disease progression and treatment response**: There are nine different genotypes of HBV, and these genotypes differ in disease progression, natural history, and treatment response. The paper explores how HBV diversity affects disease progression and treatment efficacy, and discusses the potential impact of this diversity on the development of new treatment methods. 2. **The evolution and clinical significance of HBV**: HBV is an ancient virus, and its latest reports have greatly expanded the host range of the Hepadnaviridae family (including fish and reptiles) and provided new insights into the origin and evolution of this virus family. The paper summarizes the current knowledge about HBV diversity, especially how HBV generates diversity at the individual host and population levels, and the impact of these diversities on current treatments and future cure regimens. 3. **The mechanism of persistent HBV infection**: Persistent HBV infection is mainly attributed to the presence of covalently closed circular DNA (cccDNA) in the nucleus, which is currently untargetable by treatment methods. The paper discusses the mechanism of persistent HBV infection, especially how cccDNA serves as a transcription template for viral pre - genomic RNA and mRNA, leading to the synthesis, secretion, and reinfection of viral proteins. 4. **Clinically relevant variants of HBV**: Some variants of HBV are associated with specific disease stages. For example, mutations in the basal core promoter (BCP) and pre - core (PC) regions may occur under the immune pressure against HBeAg, and these mutations are associated with the seroconversion from HBeAg - positive to - negative. The paper also discusses the impact of these variants on the loss of HBsAg, especially the differences among different genotypes. Through the exploration of these issues, the paper aims to provide a deeper understanding of HBV research, thereby promoting the development of more effective treatment strategies.